Leerink Partners Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 94.9%

Neg 0% Neu 0% Pos 94.9%

Leerink Partners analyst Daina Graybosch upgrades Summit Therapeutics (NASDAQ:SMMT) from Underperform to Market Perform and raises the price target from $12 to $13.